A multicentre phase I trial (BLOOM; NCT02228369) of 41 patients with LM from EGFR-mutated NSCLC who had disease progression on prior EGFR-TKI therapy showed an ORR of 62%, PFS of 8.6 months, and median OS of 11.0 months and reported CSF clearance in 11/40 patients (88) with 160 mg of osimertinib daily[21]. Here, EGFR is linked to non-small cell lung carcinoma.